



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Eaton, et al.

Appl. No.

10/063,685

Filed

May 8, 2002

For

A NUCLEIC ACID

OVEREXPRESSED IN KIDNEY

TUMOR AND

UNDEREXPRESSED IN LUNG

TUMOR (as amended)

Examiner

Jegatheesan Seharaseyon

Group Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 2, 2004
(Pate)

AnneMarie Kaiser, Reg. No. 37,649

RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Response to the Notice to Comply conforms the Sequence Listing to the rules of practice specified by the United States Patent and Trademark Office. Submitted herewith is a paper copy of the Sequence Listing and a copy of the Notice to Comply.

Please enter the attached sequence listing in the above-referenced application.

VERIFICATION UNDER 37 C.F.R. §1.821(f) & (g)

The sequences appearing in the attached Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. §1.821(g), no new matter is being added herewith. As required under 37 C.F.R. §1.821(f), I hereby verify that the data on the disk previously submitted and the paper copy of the Sequence Listing are identical.

Appl. No.

submitted herewith.

: 10/063,685

Filed

May 8, 2002

Applicants believe this response to Notice to Comply brings the present application into compliance with the Sequence Listing requirements. A copy of the Notice to Comply is also

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record Customer No. 30,313

(619) 235-8550

S:\DOCS\BSG\BSG-1353.DOC 081204



Notice to Comply

Application No.	Applicant(s) Eaton et al.	
Examiner J. Sehovaleyon	Art Unit 1647	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

	requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
回	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
	oplicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
\boxtimes	A statement that the content of the paper and computer readable copies are the same and, where

applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

Patentin Software Program Support

1.825(d).

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY